Nyrada Inc. (ASX:NYR)
0.5700
+0.0300 (5.56%)
At close: Mar 27, 2026
Nyrada Revenue
Nyrada had revenue of 780.37K AUD in the half year ending December 31, 2025, a decrease of -67.36%. This brings the company's revenue in the last twelve months to 2.38M, up 44.29% year-over-year. In the fiscal year ending June 30, 2025, Nyrada had annual revenue of 2.40M, down -26.07%.
Revenue (ttm)
2.38M
Revenue Growth
+44.29%
P/S Ratio
58.69
Revenue / Employee
n/a
Employees
n/a
Market Cap
139.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.40M | -845.19K | -26.07% |
| Jun 30, 2024 | 3.24M | 1.81M | 126.72% |
| Jun 30, 2023 | 1.43M | 336.16K | 30.73% |
| Jun 30, 2022 | 1.09M | -1.24M | -53.18% |
| Jun 30, 2021 | 2.34M | 1.21M | 107.57% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 21.92M |
| Starpharma Holdings | 14.58M |
| Orthocell | 9.33M |
| Dimerix | 7.42M |
| Actinogen Medical | 7.36M |
| Amplia Therapeutics | 5.01M |
| Arovella Therapeutics | 3.21M |
| Tetratherix | 2.00M |